Cormorant Asset Management »

Arrivent Biopharma shares owned by Cormorant Asset Management

Quarter-by-quarter ownership of Arrivent Biopharma (AVBP) shares owned by Cormorant Asset Management from 13F filings

Historical chart of Cormorant Asset Management investment in Arrivent Biopharma

Tip: Access up to 7 years of quarterly data

All positions including Arrivent Biopharma held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Arrivent Biopharma by Cormorant Asset Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $9.6M 515k 18.55
2024-03-31 $9.2M 515k 17.86

More positions owned by Cormorant Asset Management

Moonlake Immunotherapeutics Class A Ord (MLTX)
Corbus Pharmaceuticals Hldgs Com New (CRBP)
Arcellx Common Stock (ACLX)
Vaxcyte (PCVX)
Longboard Pharmaceuticals In (LBPH)
Eyepoint Pharmaceuticals Com New (EYPT)
Rapport Therapeutics (RAPP)
Crinetics Pharmaceuticals In (CRNX)
Edgewise Therapeutics (EWTX)
Merus N V (MRUS)
Bridgebio Pharma (BBIO)
Insmed Com Par $.01 (INSM)
Newamsterdam Pharma Company Ordinary Shares (NAMS)
Janux Therapeutics (JANX)
Axsome Therapeutics (AXSM)

View all positions for Cormorant Asset Management

Top funds holding Arrivent Biopharma

Hillhouse Capital Advisors
OrbiMed Advisors
Octagon Capital Advisors
Suvretta Capital Management
Sofinnova Ventures
Novo A/S
Sc China Holding
BlackRock
Vanguard Group
Cormorant Asset Management
Perceptive Advisors
Geode Capital Management
State Street Corporation
Woodline Partners
Charles Schwab Investment Management

View all funds holding Arrivent Biopharma